BUZZ-抑郁症药物在后期研究中失败，Neumora跌幅超过80

Reuters01-02

((自动化翻译由路透提供，请见免责声明 ))

1月2日 - ** 药物开发商Neumora Therapeutics 股价下跌82%，至1.95美元

** NMRA称其抑郁症实验药物navacaprant在一项后期试验中没有达到 (link)。

** 该药物没有减轻抑郁症状，根据疾病严重程度量表测量，该量表可追踪悲伤、睡眠减少和悲观的想法

** NMRA称，该药物在一个关键的次要目标上也没有显示出统计学意义上的显著改善

** 该公司称，截至第三季度末，其现金余额为 3.42 亿美元，将为 2026 年中期的运营提供资金支持

** 2024 年的 NMRA 下降了约 38

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2500928071?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-01-02 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500928071","market":"us","top_or_hot":-1,"title":"BUZZ-抑郁症药物在后期研究中失败，Neumora跌幅超过80","media":"Reuters","content":"<html><body><p>((自动化翻译由路透提供，请见免责声明 ))</p><p>    1月2日 - ** 药物开发商Neumora <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>  股价下跌82%，至1.95美元</p><p>** NMRA称其抑郁症实验药物navacaprant在一项后期试验中没有达到 (link)。</p><p>** 该药物没有减轻抑郁症状，根据疾病严重程度量表测量，该量表可追踪悲伤、睡眠减少和悲观的想法</p><p>** NMRA称，该药物在一个关键的次要目标上也没有显示出统计学意义上的显著改善 </p><p>** 该公司称，截至第三季度末，其现金余额为 3.42 亿美元，将为 2026 年中期的运营提供资金支持</p><p>** 2024 年的 NMRA 下降了约 38 </p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-抑郁症药物在后期研究中失败，Neumora跌幅超过80</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-抑郁症药物在后期研究中失败，Neumora跌幅超过80\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-02 20:39 北京时间&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>((自动化翻译由路透提供，请见免责声明 ))    1月2日 - ** 药物开发商Neumora Therapeutics  股价下跌82%，至1.95美元** NMRA称其抑郁症实验药物navacaprant在一项后期试验中没有达到 (link)。** 该药物没有减轻抑郁症状，根据疾病严重程度量表测量，该量表可追踪悲伤、睡眠减少和悲观的想法** NMRA称，该药物在一个关键的次要目标上也没有显示...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2500928071","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500928071","pubTimestamp":1735821553,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"((自动化翻译由路透提供，请见免责声明 ))    1月2日 - ** 药物开发商Neumora Therapeutics  股价下跌82%，至1.95美元** NMRA称其抑郁症实验药物navacaprant在一项后期试验中没有达到 (link)。** 该药物没有减轻抑郁症状，根据疾病严重程度量表测量，该量表可追踪悲伤、睡眠减少和悲观的想法** NMRA称，该药物在一个关键的次要目标上也没有显示出统计学意义上的显著改善 ** 该公司称，截至第三季度末，其现金余额为 3.42 亿美元，将为 2026 年中期的运营提供资金支持** 2024 年的 NMRA 下降了约 38","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","NMRA":"Neumora Therapeutics, Inc."},"translate_title":"BUZZ-Neumora drops more than 80% as depression drug fails in late-stage study","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NMRA":0.83},"content_text":"((自动化翻译由路透提供，请见免责声明 ))    1月2日 - ** 药物开发商Neumora Therapeutics  股价下跌82%，至1.95美元** NMRA称其抑郁症实验药物navacaprant在一项后期试验中没有达到 (link)。** 该药物没有减轻抑郁症状，根据疾病严重程度量表测量，该量表可追踪悲伤、睡眠减少和悲观的想法** NMRA称，该药物在一个关键的次要目标上也没有显示出统计学意义上的显著改善 ** 该公司称，截至第三季度末，其现金余额为 3.42 亿美元，将为 2026 年中期的运营提供资金支持** 2024 年的 NMRA 下降了约 38","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500928071"}